Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 538 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rash Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris

NCT01193764
View directory record Official record
Conditions
Acne
Interventions
100% cocoa powder, gelatin (Gelita)
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

NCT00696449
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, frequent visits, electronic reminder, Parent reminder, Standard of care
Drug · Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

NCT04633616
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis, Acne
Interventions
Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

NCT01293552
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ANT-1207, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Miami, Florida • West Palm Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

NCT00687908
View directory record Official record
Conditions
Acne
Interventions
Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
San Diego, California • Denver, Colorado • Longmont, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris

NCT02661958
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-1, S6G5T-5, S6G5T-6, S6G5T-7, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

CD71 in Dried Blood Spots in Healthy Males

NCT04073849
View directory record Official record
Conditions
Healthy Athletes
Interventions
EPOGEN® (epoetin alfa), Normal Saline
Drug · Other
Lead sponsor
Sports Medicine Research and Testing Laboratory
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 30, 2026, 7:02 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

NCT04612790
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Centennial, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 30, 2026, 7:02 AM EDT
Completed No phase listed Observational Results available

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT00709878
View directory record Official record
Conditions
Skin Rash
Interventions
Skin Biopsy of Skin Rash Secondary to EGFRI Use
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 7:02 AM EDT
Completed No phase listed Observational

Adherence and Clinical Correlates in Persons With HIV on TAF

NCT05335590
View directory record Official record
Conditions
Hiv
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 7:02 AM EDT
Not listed Phase 4 Interventional

A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne

NCT01422785
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin phosphate 1.2%/tretinoin 0.025% gel alone, clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Drug
Lead sponsor
Zeichner, Joshua, M.D.
Individual
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

NCT01019603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene, Tazaroc Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 30, 2026, 7:02 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

NCT07863193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Denifanstat, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Bryant, Arkansas • Fremont, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

NCT00834210
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone, Tazarotene
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Not applicable Interventional Results available

A Novel Method to Improve Acne Outcomes

NCT01176955
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Internet survey, Benzoyl peroxide 5% gel
Behavioral · Drug
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 30, 2026, 7:02 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

NCT04060550
View directory record Official record
Conditions
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
Interventions
Xolair
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
16 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

NCT00671749
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene gel, 0.3%, clindamycin/benzoyl peroxide gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Warren, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"

NCT01694433
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Calcipotriene, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

Timolol for the Treatment of Acne and Rosacea

NCT02774590
View directory record Official record
Conditions
Acne Vulgaris, Rosacea
Interventions
Timolol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne

NCT02404285
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Next Science Acne Gel, Vehicle
Drug
Lead sponsor
Next Science TM
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Jacksonville, Florida • Ponte Vedra, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Results available

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

NCT03743038
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101 vehicle, Hydro-alcohol solution
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Blue Light Therapy of C. Acnes

NCT04300010
View directory record Official record
Conditions
Acne
Interventions
5% Topical Benzoyl Peroxide Gel, Blue Light Therapy
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT00422240
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%, Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 30, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib Lichen Planus

NCT03697460
View directory record Official record
Conditions
Lichen Planus
Interventions
INCB018424
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 30, 2026, 7:02 AM EDT